Daclizumab: A Potential Asthma Therapy?

Publisher： Bentham Science Publishers

E-ISSN： 2212-2710|4|3|214-221

ISSN： 1872-213X

Source： Recent Patents on Inflammation & Allergy Drug Discovery, Vol.4, Iss.3, 2010-11, pp. : 214-221

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Experimental Approaches Towards Allergic Asthma Therapy-Murine Asthma Models

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 4, Iss. 1, 2010-01 ,pp. : 37-53

Bentham Science Publishers

Access to resources Recommend Favorite

CD48 as a Novel Target in Asthma Therapy

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 1, Iss. 1, 2007-02 ,pp. : 9-12

Bentham Science Publishers

Access to resources Recommend Favorite

A Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab) in the Therapy of Moderate-to-Severe Allergic Asthma

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 1, Iss. 3, 2007-01 ,pp. : 225-231

Bentham Science Publishers

Access to resources Recommend Favorite

Platelet-Activating Factor (PAF): A Review of its Role in Asthma and Clinical Efficacy of PAF Antagonists in the Disease Therapy

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 2, Iss. 1, 2008-01 ,pp. : 72-76

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis

By  

Recent Patents on Materials Science, Vol. 5, Iss. 3, 2012-07 ,pp. : 222-240

Bentham Science Publishers

Access to resources Recommend Favorite